In this video, Dr. Brian G.M. Durie explains how high-dose melphalan therapy that precedes an ASCT may cause some side effects and how an ASCT itself may result in some low-risk complications.

BOTTOM LINE:
Autologous stem cell transplant is still a recommended therapy, if feasible, and it is mostly manageable.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org.

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

Previous Post
Fourth of July in 2018: A Time of Celebration and Challenges
Next Post
Can Kyprolis® (carfilzomib) be administered once a week, rather than twice a week?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.